

## ARTICLE

# SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions

Claire Beneteau<sup>\*1</sup>, Hélène Cavé<sup>2</sup>, Anne Moncla<sup>3</sup>, Nathalie Dorison<sup>4</sup>, Arnold Munnich<sup>5</sup>, Alain Verloes<sup>6</sup> and Bruno Leheup<sup>7</sup>

<sup>1</sup>Service de Médecine Infantile III et Génétique Clinique, Hôpital d'Enfants CHU de Nancy, Vandoeuvre Cedex, Faculté de Médecine Nancy Université Henri Poincaré, Vandoeuvre, Cedex, Vandoeuvre, France; <sup>2</sup>Département de Génétique, Hôpital Robert Debré, Paris, France; <sup>3</sup>Département de Génétique Médicale, Hôpital d'enfants de la Timone, CHU de Marseille, France; <sup>4</sup>Service de Neuropédiatrie pathologie du développement, Hôpital Armand Trousseau, Paris, France; <sup>5</sup>Service de Génétique Médicale, Hôpital Necker Enfants Malades, Paris, France; <sup>6</sup>Département de Génétique, Hôpital Robert Debré, Paris, France; <sup>7</sup>Service de Médecine Infantile III et Génétique Clinique, Hôpital d'Enfants CHU de Nancy, Vandoeuvre Cedex, Faculté de Médecine Nancy Université Henri Poincaré, Vandoeuvre Cedex, Vandoeuvre, France

We report five cases of multiple giant cell lesions in patients with typical Noonan syndrome. Such association has frequently been referred to as Noonan-like/multiple giant cell (NL/MGCL) syndrome before the molecular definition of Noonan syndrome. Two patients show mutations in *PTPN11* (p.Tyr62Asp and p.Asn308Asp) and three in *SOS1* (p.Arg552Ser and p.Arg552Thr). The latter are the first *SOS1* mutations reported outside *PTPN11* in NL/MGCL syndrome. MGCL lesions were observed in jaws ('cherubism') and joints ('pigmented villonodular synovitis'). We show through those patients that both types of MGCL are not *PTPN11*-specific, but rather represent a low penetrant (or perhaps overlooked) complication of the dysregulated RAS/MAPK signaling pathway. We recommend discarding NL/MGCL syndrome from the nosology, as this presentation is neither gene-nor allele-specific of Noonan syndrome; these patients should be described as Noonan syndrome with MGCL (of the mandible, the long bone...). The term cherubism should be used only when multiple giant cell lesions occur without any other clinical and molecular evidence of Noonan syndrome, with or without mutations of the *SH3BP2* gene.

*European Journal of Human Genetics* (2009) 17, 1216–1221; doi:10.1038/ejhg.2009.44; published online 8 April 2009

**Keywords:** Noonan-like syndrome; *SOS1*; *PTPN11*; cherubism; pigmented villonodular synovitis; multiple giant cell lesions

## Introduction

Mutations in genes of the RAS/MAPK signaling pathway have been reported in several developmental disorders. In most cases, those mutations are expected to lead to overactivation of the pathway. Implications of germline

mutations in the RAS/MAPK pathway in development and malignancies have been reviewed recently.<sup>1–3</sup> Five core phenotypes are associated with constitutionally deregulated RAS/MAPK signaling: Noonan syndrome (NS), LEOPARD syndrome (LS), cardiofaciocutaneous syndrome (CFC), Costello syndrome (CS), and neurofibromatosis 1. They are collectively referred to as the neuro-CFC syndromes.<sup>4</sup>

The dominantly inherited NS is a well-defined syndrome characterized by typical facial dysmorphism, cardiac anomalies, growth retardation, and inconstant cognitive impairment. Birth prevalence is estimated between 1/1000

\*Correspondence: Dr C Beneteau, Service de Médecine Infantile III et Génétique Clinique, Hôpital d'Enfants CHU de Nancy, Vandoeuvre, Cedex 54511, France.

Tel: + 33 383 154 500; Fax: + 33 383 154 647

E-mail: c.beneteau@chu-nancy.fr

Received 16 July 2008; revised 3 February 2009; accepted 11 February 2009; published online 8 April 2009

and 1/2500. Mutations in *PTPN11*<sup>5</sup> are reported in about 50% of cases, *SOS1*<sup>6,7</sup> in 10–20%, *RAF1*<sup>8</sup> and *KRAS*,<sup>9</sup> both in less than 5%. Rare patients with *BRAF*, *MEK1*, or *MEK2* may exhibit an NS phenotype,<sup>10</sup> although most of them have CFC syndrome.

Several 'Noonan-like (NL) entities' have been delineated. When NS and CFC genes were discovered, it became evident that those variants reflected intrinsic, non-allele-specific variability in the expression of those genes. The NL/multiple giant cell lesion (NL/MGCL) syndrome is one of those rare variants that were once considered as bona fide syndromes. MGCLs, also known as central giant cell lesions or giant cell granulomas, are non-neoplastic lesions characterized by a proliferation of granulation tissue containing many multinucleated giant cells (Langhans giant cells) embedded in a fibrous stroma. MGCLs are found in several disorders, among which two are related to NS, 'cherubism' and pigmented villonodular synovitis. MGCLs of the jaws are osteoclast-rich lesions. Most cases are sporadic, unilateral, and more common in women. By contrast, a bilateral, symmetric form is observed in a rare autosomal dominant disorder, called cherubism syndrome, with male preponderance. Cherubism syndrome is characterized by bilateral swelling of the jaws, full cheeks, hypertelorism, prognathism, malocclusion, and oligodontia. Enlargement of the cheeks first appears around the third or fourth year of life, usually stabilizes after puberty and abates by the third decade. Cystic lesions are symmetrical. On X-rays, they appear as multilocular cysts that expand the cortical plate and may displace tooth buds and erode roots. Local aggressiveness of the tumor is variable. Histologically, the lesions are indistinguishable from those of the sporadic, unilateral cases. They are similar to brown tumors of hyperparathyroidism. In the adult, the cystic lesions give place to sclerosis with progressive calcifications. Cherubism syndrome is fully penetrant in men and partially (50–70%) penetrant in women. A majority of cases have been associated with missense mutations affecting a 6-amino-acid sequence (aa 33–aa 38) upstream of the SH2 domain of the SH3BP2 protein. The corresponding gene *SH3BP2* (Src homology 3-binding protein 2) maps to chromosome 4p16.3. Sporadic MGCLs of the jaw are not associated with the germline or somatic mutations of *SH3BP2*.<sup>11</sup>

Pigmented villonodular synovitis (PVS) is a benign proliferative disorder of the synovial tissue, which may affect the synovial-lined large joints (more commonly the knee and ankle) or tendon sheaths of small joints. It is more frequent in women. Patients usually present with painless swelling of the joints. PVS is sporadic and its pathogenesis is unknown. Histologically, PVS lesions are central giant cell lesions similar to those seen with cherubism. The presence of hemosiderin in giant cells and surrounding stroma gives the tissue a characteristic pigmentation. The lesions tend to be hyperplastic,

hypervascular and hemorrhagic. PVS typically invades the surrounding tissues, including the subchondral bone, resulting in bone cyst formation.

NL/MGCL syndrome combines clinical signs of NS with multiple giant cell lesions similar to those observed in cherubism and PVS.<sup>12–14</sup> Before the discovery of the NS-causing genes, nine patients have been described with NS and cherubism<sup>15–20</sup> and only one with NS and PVS.<sup>21</sup> Nine patients with NS and cherubism have been reported with *PTPN11* mutations.<sup>13,14,22–25</sup> These mutations are not specific (the same variation can be observed with or without MGCL lesions, even in a single pedigree).

To date, no mutations in *SOS1*, *KRAS*, *RAF1*, *BRAF* or *MEK* have been reported in patients with this phenotype and no *PTPN11* alteration. Similarly, no mutation has been reported insofar in patients with NS and PVS. We report five cases of NS with MGCL, including three patients with *SOS1* mutations.

## Clinical cases reports

Clinical data of the five cases are summarized in Table 1.

### Patient 1

The first patient had a birth length (BL) of 55 cm (>90th centile), a birth weight (BW) of 4288 g (>90th centile) and an occipitofrontal head circumference (OFC) of 35.5 cm. (50–75th centile) at term. Stenosis of the pulmonary valve was diagnosed in early infancy. We saw him first at the age of 8 years. He has typical features for NS. His karyotype was 46, XY, inv(9) (p11q13). An X-ray survey and CT scan showed bilateral radiolucent cysts of the mandible that were not operated. Eruption of the incisors was delayed. He had a normal stature and no learning difficulties.

### Patient 2

This patient was born at 41 weeks of gestation (WG) with normal birth parameters: BL 48 cm (25th centile) and BW 3610 g (75–90th centile). Mitral valve prolapse was diagnosed at the age of 10 years. We saw him first at 11 years. He had typical NS, with cryptorchidism and decreased platelet aggregation function. Cerebral MRI showed moderate ventriculomegaly. Cysts of the mandible were present. At the age of 12 years, he had normal stature, dyslexia, and learning difficulties. His IQ was 93.

### Patient 3

This patient was born at 39 WG. Hydramnios was present during pregnancy. BW was 3950 g (>90th centile), and BL 51 cm (90th centile). Stenosis of the pulmonary artery and atrial septal defect were diagnosed at birth. Clinical features were typical for NS. At 12 years, PVS of the left ankle was diagnosed and confirmed by bone scintigraphy, MRI, and biopsy. At the age of 15 years, his height was at

**Table 1** Clinical features of patients (Pts) 1–5

	Pt 1	Pt 2	Pt 3	Pt 4	Pt 5
<i>Craniofacial</i>					
Full face	+	+	+	+	+
Hypertelorism	+	+	+	–	–
Ptosis	–	–	–	+	+
Low nasal bridge	+	–	–	+	+
Epicanthal folds	+	–	–	+	+
Low-set and posteriorly angulated ears with thick helices	+	+	+	+	+
Low posterior hairline	+	–	+	+	+
Tall forehead	+	–	+	+	+
Prognathism	–	–	–	+	–
Micrognathia	+	–	–	–	+
Malocclusion	–	–	–	–	–
Oligodontia	–	–	–	–	–
<i>Cardiovascular</i>					
Stenotic pulmonary valve	+	–	–	+	+
Pulmonary artery stenosis	–	–	+	–	–
Septal defect	–	–	–	–	–
<i>Growth</i>					
Short stature	–	–	+	+	+
<i>Skeletal</i>					
Pectus carinatum/excavatum, sternal defect	+	–	+	+	–
Cubitus valgus	–	–	–	–	–
<i>Neurological</i>					
Learning difficulties	–	+	–	+	–
Psychiatric disorder	–	–	–	–	+
<i>Genitourinary</i>					
Cryptorchidism	–	+	+	+	–
Puberty (N and D)	NA	N	D	D	NA
<i>Mutation</i>					
SH3BP2	NA	NA	NA	NA	NA
PTPN11	–	–	–	+	+
SOS1	+	+	+	NA	NA
<i>X-rays</i>					
Cystic lesions of bones	+	+	–	+	+
<i>Histopathology</i>					
MGCL in cellular fibrous tissue.	NA	NA	+	+	NA

+, present; –, absent; D, delayed; N, normal; MGCL, multiple giant cell; NA, information not available.

–2 DS. He had delayed puberty, left cryptorchidism, and no learning disabilities. There was no involvement of the jaws.

#### Patient 4

This boy was born at 41 WG, BW was 3850 g (75th centile), BL 51 cm (50th centile), and OFC 35.5 cm (50–75th centile). Stenosis of the pulmonary valve was diagnosed after birth. He carried a maternally inherited balanced translocation 46, XY, t(3;22) (p21q13)mat. At 5 years of age, he developed a cherubic appearance (Figure 1). Multiple radiolucent lesions in both ascending rami of the mandible were found (Figure 1). Partial bilateral resection was carried out at the age of 6 years. Pathological examination showed MGCL. Progressive bilateral enlargement of lesions and recurrence of the tumor in the ascending ramus of the right

mandible at the age of 8 made further surgery mandatory. He had speech delay and learning disabilities. At 8 years of age, his DQ was 87, with specific visual constructional problems and discrepancy between verbal and performance scores. Final height was 162 cm (–1.9 DS).

#### Patient 5

This boy was born at 38 WG, BW was 3320 g (50th centile), and BL 51 cm (75th centile). His father was 58 years of age at conception. Valvular and supra-valvular pulmonary stenoses were diagnosed during gestation. NS was suspected at birth because of his facial features. A left unilocular mandibular radiolucency was coincidentally discovered at 12 years on an orthopantomogram, and confirmed on a CT scan of the mandible (Figure 2). A histopathological



**Figure 1** Patient 4. (a) and (b) Facial appearance in adolescence after surgical correction of left eyelid ptosis. Characteristic gestalt of NS. The facial fullness with swollen cheeks and mild prognathism are the consequences of mandibular MGCL. (c) CT scan of the mandible with bilateral radiolucent lacunae corresponding to the extensive bilateral MGCL, more extensive on the left. (d) Partial orthopantomogram of the left mandible showing the expansive lesions.

examination of the lesion disclosed MGCL. His height was at  $-2DS$  at 12 years. He had had no difficulties at school, but was depressive.

### Molecular investigations

Direct sequencing of the *PTPN11* coding region (exons 1–15) was carried out in the five patients. Exons 16–23 of *SOS1* were further sequenced in the patients 1, 2, and 3 using standard protocols. On the basis of RefSeq NM\_005633.2, the mutation c.1656G>C (p.Arg552Ser) was found in exon 11 of *SOS1* in patients 1 and 3 (who are not related). This mutation has been reported earlier in common NS.<sup>26,27</sup> The mutation c.1655G>C (p.Arg552Thr) was found in exon 11 of *SOS1* in patient 2. This mutation has never been reported. On the basis of RefSeq NM\_002834.3, mutations c.184T>G (p.Tyr62Asp) in exon 3 and c.922A>G (p.Asn308Asp) in exon 8 of *PTPN11* were found in patients 4 and 5, respectively. These two mutations have been reported earlier in NS.<sup>26,27</sup> No *PTPN11* mutations were found in patients 1, 2, and 3.


### Discussion

To date, at least 23 patients with NL/MGCL phenotype have been reported under various names, most of them without molecular data.<sup>13–15,17,19–24,28,29</sup> Two were

familial.<sup>20,28</sup> Taking these reports into account, 11 patients carrying a mutation of *PTPN11* were found among 18 NL/MGCL-screened cases (61 %). In a series of eight patients with cherubism, Jafarov *et al*<sup>24</sup> found three with a mutation in *SH3BP2* and two with a mutation in *PTPN11*. One of the latter has clinical features of NL/MGCL syndrome; the other one was not described. None of them carried a mutation in both genes.

MGCL has been reported with other phenotypes linked to the RAS/MAPK pathway. A case of MGCL was reported with LS.<sup>30</sup> Sarkozy *et al*<sup>31</sup> reported a patient harboring a mutation in *PTPN11* with a complex phenotype progressing throughout the years from NS toward LS and NL/MGCL. Interestingly, some patients with NF1 have been reported with MGCLs of various locations, including the jaws.<sup>32–36</sup>

Before the elucidation of the molecular basis of NS, some authors had suggested that the association of MGCL with an NS phenotype was an independent NL entity, the NL/MGCL syndrome. The mutations observed in patients with MGCL are not different from those observed in NS without any bone anomalies. A mutation can be observed with or without granulomas in the same family. NL/MGCL syndrome must be considered as a part of the NS spectrum, and not as an NL disorder. We strongly support the idea of discarding the use of NL/MGCL syndrome, Noonan-cherubism or other specific names to refer to this presentation of NS. NS with MGCL may be used to describe the



**Figure 2** Patient 5. (a): Partial orthopantomogram of the jaw showing cystic erosion of the mandible. (b) CT scan of the lower jaw showing bilateral cysts invading the mandibular rami.

affected patients. Cherubism should only be used for patients with sporadic or *SH3BP2*-related multiple giant cell lesions of the jaws, without any evidence of NS.

The pathophysiology of MGCL remains mysterious. *SH3BP2* codes for the multidomain scaffolding protein, *SH3BP2*,<sup>37</sup> a critical regulator of myeloid cell responses. Mutations in cherubism lead to a gain of function or act in a dominant-negative manner, leading to abnormal gain of myeloid cell function. Osteoclasts are multinucleated cells derived from the myeloid lineage. The major factors for osteoclast differentiation are RANKL (through its receptor RANK) and M-CSF; *SH3BP2* functions downstream of both. It contributes to the activation of ERK, which is at the bottom of the MAPK-dependent pathway, leading to the production of TNF $\alpha$  and to the activation of the calcineurin/NFAT (nuclear factor of activated T cells) pathway and its downstream effector, NFATc1 (nuclear factor of activated T cells c1 isoform).<sup>38,39</sup> Although these observations give a frame to explain granuloma formation with RAS/MAPK-related genes on the one hand, and *SH3BP2* on the other, whether this low penetrant manifestation results from the interference of modifier genes with the RAS/MAPK pathway or from an exogenous stimulus leading to focal development of granuloma in a genetically permissive environment remains unknown.

In summary, we present five patients with NL/MGCL. Three of them have *SOS1* mutations (two patients with facial giant cell lesions and one patient with PVS of the ankle joint). The two others have *PTPN11* mutations. NL/MGCL syndrome, previously regarded as an entity distinct from NS, is a phenotypic variation within the NS spectrum. MGCL appears to be a non-gene-specific and non-allele-specific manifestation of dysregulated RAS/MAPK pathway.

#### Note added in proof

Although this study was under reviewing process, two independent reports confirmed our observations. In this Journal, cherubism was reported in four patients with NS and *SOS1* mutations, and in three patients with CFC and *BRAF* mutations.<sup>40</sup> A *SOS1* mutation<sup>41</sup> was reported in a single patient with NS and PVS. These reports confirm that MGCL is a rare complication of the deregulated RAS/MAPK pathway.

#### References

- 1 Tartaglia M, Martinelli S, Stella L *et al*: Diversity and functional consequences of germline and somatic *PTPN11* mutations in human disease. *Am J Hum Genet* 2006; **78**: 279–290.
- 2 Gelb BD, Tartaglia M: Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. *Hum Mol Genet* 2006; **15** (Spec No 2): R220–R226.
- 3 Schubert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. *Nat Rev Cancer* 2007; **7**: 295–308.
- 4 Bentires-Alj M, Kontaridis MI, Neel BG: Stops along the RAS pathway in human genetic disease. *Nat Med* 2006; **12**: 283–285.
- 5 Tartaglia M, Mehler EL, Goldberg R *et al*: Mutations in *PTPN11*, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet* 2001; **29**: 465–468.
- 6 Roberts AE, Araki T, Swanson KD *et al*: Germline gain-of-function mutations in *SOS1* cause Noonan syndrome. *Nat Genet* 2007; **39**: 70–74.
- 7 Tartaglia M, Pennacchio LA, Zhao C *et al*: Gain-of-function *SOS1* mutations cause a distinctive form of Noonan syndrome. *Nat Genet* 2007; **39**: 75–79.
- 8 Razaque MA, Nishizawa T, Komoike Y *et al*: Germline gain-of-function mutations in *RAF1* cause Noonan syndrome. *Nat Genet* 2007; **8**: 1013–1017.
- 9 Schubert S, Zenker M, Rowe SL *et al*: Germline *KRAS* mutations cause Noonan syndrome. *Nat Genet* 2006; **38**: 331–336.
- 10 Nava C, Hanna N, Michot C *et al*: CFC and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome. *J Med Genet* 2007; **12**: 763–771.
- 11 Idowu BD, Thomas G, Frow R *et al*: Mutations in *SH3BP2*, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. *Br J Oral Maxillofac Surg* 2008; **46**: 229–230.
- 12 Cohen Jr MM, Gorlin RJ: Noonan-like/multiple giant cell lesion syndrome. *Am J Med Genet* 1991; **40**: 159–166.
- 13 Lee JS, Tartaglia M, Gelb BD *et al*: Phenotypic and genotypic characterisation of Noonan-like/multiple giant cell lesion syndrome. *J Med Genet* 2005; **42**: e11.
- 14 Wolvius EB, de LJ, Smeets EE *et al*: Noonan-like/multiple giant cell lesion syndrome: report of a case and review of the literature. *J Oral Maxillofac Surg* 2006; **64**: 1289–1292.
- 15 Cancino CM, Gaiao L, Sant'Ana FM *et al*: Giant cell lesions with a Noonan-like phenotype: a case report. *J Contemp Dent Pract* 2007; **8**: 67–73.

- 16 Lee SM, Cooper JC: Noonan syndrome with giant cell lesions. *Int J Paediatr Dent* 2005; **15**: 140–145.
- 17 Addante RR, Breen GH: Cherubism in a patient with Noonan's syndrome. *J Oral Maxillofac Surg* 1996; **54**: 210–213.
- 18 Betts NJ, Stewart JC, Fonseca RJ *et al*: Multiple central giant cell lesions with a Noonan-like phenotype. *Oral Surg Oral Med Oral Pathol* 1993; **76**: 601–607.
- 19 Levine B, Skope L, Parker R: Cherubism in a patient with Noonan syndrome: report of a case. *J Oral Maxillofac Surg* 1991; **49**: 1014–1018.
- 20 Dunlap C, Neville B, Vickers RA *et al*: The Noonan syndrome/cherubism association. *Oral Surg Oral Med Oral Pathol* 1989; **67**: 698–705.
- 21 Minisola G, Porzio V, Ceralli F *et al*: Polyarticular pigmented villonodular synovitis associated with multiple congenital anomalies. A case of Noonan-like/multiple giant cell lesion syndrome. *Clin Exp Rheumatol* 1996; **14**: 207–210.
- 22 Tartaglia M, Kalidas K, Shaw A *et al*: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. *Am J Hum Genet* 2002; **70**: 1555–1563.
- 23 Bertola DR, Pereira AC, Albano LM *et al*: PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. *Genet Test* 2006; **10**: 186–191.
- 24 Jafarov T, Ferimazova N, Reichenberger E: Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. *Clin Genet* 2005; **68**: 190–191.
- 25 Bertola DR, Pereira AC, Passetti F *et al*: Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. *Am J Med Genet A* 2005; **136**: 242–245.
- 26 Maheshwari M, Belmont J, Fernbach S *et al*: PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. *Hum Mutat* 2002; **20**: 298–304.
- 27 Tartaglia M, Kalidas K, Shaw A *et al*: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. *Am J Hum Genet* 2002; **70**: 1555–1563.
- 28 Bertola DR, Kim CA, Pereira AC *et al*: Are Noonan syndrome and Noonan-like/multiple giant cell lesion syndrome distinct entities? *Am J Med Genet* 2001; **98**: 230–234.
- 29 Kirk JM, Betts PR, Butler GE *et al*: Short stature in Noonan syndrome: response to growth hormone therapy. *Arch Dis Child* 2001; **84**: 440–443.
- 30 Wendt RG, Wolfe F, McQueen D *et al*: Polyarticular pigmented villonodular synovitis in children: evidence for a genetic contribution. *J Rheumatol* 1986; **13**: 921–926.
- 31 Sarkozy A, Obregon MG, Conti E *et al*: A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. *Eur J Hum Genet* 2004; **12**: 1069–1072.
- 32 Ruggieri M, Pavone V, Polizzi A *et al*: Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999; **87**: 67–72.
- 33 Edwards PC, Fantasia JE, Saini T *et al*: Clinically aggressive central giant cell granulomas in two patients with neurofibromatosis 1. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; **102**: 765–772.
- 34 Krammer U, Wimmer K, Wiesbauer P *et al*: Neurofibromatosis 1: a novel NF1 mutation in an 11-year-old girl with a giant cell granuloma. *J Child Neurol* 2003; **18**: 371–373.
- 35 Van Damme PA, Mooren RE: Differentiation of multiple giant cell lesions, Noonan-like syndrome, and (occult) hyperparathyroidism. Case report and review of the literature. *Int J Oral Maxillofac Surg* 1994; **23**: 32–36.
- 36 Yazdizadeh M, Tapia JL, Baharvand M *et al*: A case of neurofibromatosis-Noonan syndrome with a central giant cell granuloma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2004; **98**: 316–320.
- 37 Ueki Y, Tiziani V, Santanna C *et al*: Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. *Nat Genet* 2001; **28**: 125–126.
- 38 Ueki Y, Lin CY, Senoo M: Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 'cherubism' mice. *Cell* 2007; **128**: 71–83.
- 39 Lietman SA, Yin L, Levine MA: SH3BP2 is an activator of NFAT activity and osteoclastogenesis. *Biochem Biophys Res Commun* 2008; **371**: 644–648.
- 40 Neumann TE, Allanson J, Kavamura I *et al*: Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. *Eur J Hum Genet* 2008.
- 41 Mascheroni E, Digilio MC, Cortis E *et al*: Pigmented villonodular synovitis in a patient with Noonan syndrome and SOS1 gene mutation. *Am J Med Genet A* 2008; **146A**: 2966–2967.